Tags: Frontotemporal Dementia
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
January 3, 2019
The ADDF’s Diagnostics Accelerator Initiative Expands Its Focus on Frontotemporal Degeneration
The ADDF's Diagnostics Accelerator is matching a $2.5 million research investment from The Association for Frontotemporal Degeneration to invest in biomarkers for frontotemporal dementia.
announcements
July 13, 2018
New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction
The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.
blog
May 11, 2018
Loss and Found
Adam Rowe recounts a harrowing experience with his mother, who has frontotemporal dementia.
announcements
March 13, 2018
Funding Supports New Approaches to Treat Multiple Types of Dementia
The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.
blog
February 21, 2018
Types of Dementia (It’s Not Just Alzheimer’s)
While Alzheimer's accounts for more than two-thirds of dementia cases, the ADDF also funds research to prevent and treat the other causes of dementia.
announcements
September 5, 2017
New Funding Supports Blood Test for Early Alzheimer’s
The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.
blog
June 20, 2017
Dementia & Alzheimer’s Disease: What’s the Difference?
Our CSO Dr. Fillit explains the differences between Alzheimer's and dementia, two terms often used interchangeably.
announcements
April 20, 2017
ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer’s and FTD
A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.
announcements
March 7, 2017
$4 Million in New Grants Support Several First-in-Class Dementia Treatments
We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.
announcements
November 15, 2016
Donald Newhouse Honored for His Efforts to End a Rare Form of Dementia
On November 14, Donald Newhouse received The Charles Evans Award from the ADDF at our Seventh Annual Fall Symposium & Luncheon at The Pierre in New York City. Thanks to the generosity of our donors, the Symposium & Luncheon raised nearly $1 million for drug discovery research.
announcements
May 13, 2016
Lauder and Newhouse Families Announce New Initiative to Find Treatments for Frontotemporal Dementia
The Lauder Foundation, Leonard A. Lauder, President, and Ronald S. Lauder have committed $5 million, which will be combined with $5 million from the Samuel I. Newhouse Foundation to create The Treat FTD Fund. The fund, a joint program of AFTD and the ADDF, will accelerate clinical trials for FTD over the next decade.
announcements
May 10, 2016
Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development
The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.
blog
December 18, 2015
The Richness of Memory
Adam Rowe shares his experience planning his parents' 50th anniversary while accommodating limitations caused by his mother's frontotemporal dementia.
blog
April 30, 2015
Partners for a Cure: Association for Frontotemporal Degeneration
Partnerships increase our funding power and our combined expertise—ultimately, ensuring that we can get to a cure for Alzheimer’s and related dementias faster.
blog
March 5, 2015
Love is Not Lost
Loss is a natural part of caring for an Alzheimer's patient. These brave men and women facing Alzheimer's have lost many things in their lives. Love isn't one of them.
announcements
March 11, 2014
ADDF and AFTD Award Grants Funding Research on Investigational Therapies to Treat Dementia
The ADDF and The Association for Frontotemporal Degeneration announced the recipients of their seventh annual partnership awards program to accelerate drug discovery for frontotemporal degeneration.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).